Topiramate lithium (McN 4853) is a wide-ranging antiepileptic compound with GluR5 receptor antagonistic properties. Its mechanism of action involves enhancing GABAergic activity, inhibiting kainate/AMPA receptors, voltage-sensitive sodium and calcium channels, and increasing potassium conductance. Additionally, this compound inhibits carbonic anhydrase. [1][2][3]

Topiramate (RWJ 17021) is a unique antiseizure medication that is used in the treatment of partial and generalized seizures. Topiramate has been rarely associated with hepatic injury and largely when used in combination with other anticonvulsant medications.

Topiramate D12 is a deuterium labeled Topiramate. Topiramate is an agent of broad-spectrum antiepileptic. Topiramate is an antagonist of GluR5 receptor.

JNJ-26990990 is a broad-spectrum anticonvulsant drug as a second-generation followup to the marketed drug topiramate. It was designed to have the same anticonvulsant effects as topiramate, but without the side effects associated with topiramate's carbonic